A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home AIMD Business EnteroMedics Reports $123k Revenue from Sales of its Maestro RC IPG for Treatment of Obesity
formats

EnteroMedics Reports $123k Revenue from Sales of its Maestro RC IPG for Treatment of Obesity

Today EnteroMedics recorded revenue for the first time since it was incorporated nearly eight years ago. The company reported revenue of about $123,000 in the first quarter of the year from the sale of its Maestro RC implantable vagus nerve stimulation system for treating obesity. Revenue was generated through sales by its distribution partner in Australia.

This is an important step for an implantable device company that faced very tough times in 2009 after its US clinical trial failed to meet a critical effectiveness goal.  EnteroMedics is currently conducting a pivotal trial that is expected to end in Q4 2012. EnteroMedics expects to file a premarket approval application with the FDA in the first half of 2013 if the data from the trial is positive.

 

 

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on EnteroMedics Reports $123k Revenue from Sales of its Maestro RC IPG for Treatment of Obesity  comments